Mylan Inc.
Quick facts
| Founded | 1961 |
|---|
Marketed products
- Bethkis® · Infectious Disease / Pulmonary
Bethkis is an inhaled antibiotic that delivers tobramycin directly to the lungs to kill Pseudomonas aeruginosa bacteria in cystic fibrosis patients. - Cayston® · Respiratory / Infectious Disease
Cayston is an inhaled antibiotic that disrupts bacterial biofilm formation and kills Pseudomonas aeruginosa in the lungs. - Dymista · Other
- Humira® (Adalimumab) · Immunology
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. - Sulfamylon® For 5 % Topical Solution · Dermatology / Burn Care / Infectious Disease
Mafenide acetate inhibits bacterial folic acid synthesis by competing with para-aminobenzoic acid, thereby exerting broad-spectrum antimicrobial activity against burn wound pathogens. - TOBI® PODHALER®
- Topical Antimicrobial/Antifungal Medications · Dermatology/Infectious Disease
Topical antimicrobial and antifungal medications work by disrupting microbial cell membranes, inhibiting fungal cell wall synthesis, or interfering with microbial protein synthesis to eliminate or inhibit growth of bacteria and fungi on skin surfaces.
Phase 3 pipeline
- FlexPen NovoLog® · Diabetes
NovoLog is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells. - MYL-1401A (Adalimumab) · Immunology
MYL-1401A is a biosimilar of adalimumab that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. - MYL-1401H · Oncology
MYL-1401H is a biosimilar of trastuzumab that binds to HER2 receptors on cancer cells to inhibit their growth and promote immune-mediated cell death. - MYL- 1401O · Oncology
MYL-1401O is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to prevent tumor angiogenesis. - MYL-1601D Product · Diabetes
MYL-1601D Product is a generic version of a medication that helps to lower blood sugar levels in people with type 2 diabetes. - Mylan's insulin glargine · Diabetes
Insulin glargine is a long-acting insulin analog that mimics the action of human insulin to lower blood glucose levels. - Placebo for Revefenacin
This is a placebo, meaning it has no active pharmacological effect. - Placebo for Spiriva Handihaler®
This is a placebo, meaning it has no active therapeutic effect. - TD-4208 · Cardiovascular
TD-4208 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Mylan Inc.
What are Mylan Inc.'s marketed drugs?
Top marketed products include Bethkis®, Cayston®, Dymista, Humira® (Adalimumab), Sulfamylon® For 5 % Topical Solution, TOBI® PODHALER®.
What is Mylan Inc.'s pipeline?
Mylan Inc. has 9 drugs in Phase 3, 5 in Phase 2, 4 in Phase 1. Late-stage candidates include FlexPen NovoLog®, MYL-1401A (Adalimumab), MYL-1401H, MYL- 1401O.
When was Mylan Inc. founded?
Mylan Inc. was founded in 1961.
How many employees does Mylan Inc. have?
Mylan Inc. has approximately 35,000 employees.
Related
- Bethkis® · Infectious Disease / Pulmonary
- Cayston® · Respiratory / Infectious Disease
- Dymista · Other
- Humira® (Adalimumab) · Immunology
- Sulfamylon® For 5 % Topical Solution · Dermatology / Burn Care / Infectious Disease
- Sector hub: All tracked pharma companies